Vol 11, Supp. A (2020)
Case report
Published online: 2021-01-07

open access

Page views 540
Article views/downloads 229
Get Citation

Connect on Social Media

Connect on Social Media

Loss of complete cytogenetic response after nilotinib discontinuation

Tomasz Sacha1, Joanna Wącław1


The achievement of treatment-free remission (TFR) became recently a new, important goal of chronic myelogenous leukemia (CML) therapy. The strategy to achieve durable, deep molecular response, and, subsequently, to discontinue tyrosine kinase inhibitor (TKI) is particularly attractive for younger patients, and for those, who experience long-lasting side effects that reduce substantially the quality of life. The results of many clinical trials suggest that approximately 50% of patients can achieve durable TFR. In the remaining patients, loss of major molecular response (and less frequently complete cytogenetic response [CCyR]) is the cause of treatment reintroduction. Discontinuation of TKI is considered a safe procedure. No disease progressions or deaths caused by treatment discontinuation were noted so far. Here, we present a case of a patient who lost a CCyR after discontinuation of nilotinib. The reintroduction of nilotinib resulted in the rapid achievement of CCyR and DMR (MR4).

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
  2. Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017; 35(3): 298–305.
  3. Rea D, Nicolini F, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017; 129(7): 846–854.
  4. Saussele S, Richter J, Guilhot J, et al. EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018; 19(6): 747–757.
  5. Hughes TP, Saglio G, Kantarjian H, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9): 1353–1360.
  6. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20): 2333–2340.

Hematology in Clinical Practice